Skip to main content
SpringerLink
Log in

Drug Treatments for Maintaining Remission in Crohn’s Disease

A Lifetime Cost-Utility Analysis

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

A recent literature overview has estimated the long term frequency of the main outcomes of Crohn’s disease (e.g. relapses, hospitalisations and surgery). Using these frequency data, we defined a model for the long term course of the disease. In this model, the quality-of-life (QOL) scores for the main levels of disease severity were determined by a panel of expert gastroenterologists.

We conducted a combined analysis of these long term clinical data and of this QOL information to determine the cost-utility ratio of long term maintenance therapy with mesalazine (mesalamine) in patients with inactive Crohn’s disease. After obtaining the cost-of-illness data needed for this analysis from a recent study conducted in the UK, we completed our incremental cost-utility analysis, in which mesalazine was compared with no maintenance treatment, using 2 hypothetical groups of 100 patients. These 2 groups were assumed to have the same general characteristics as those found in a group of 583 patients included in a recent meta-analysis. Our cost-utility evaluation included 5% annual discounting.

In the mesalazine group, the overall lifetime costs for the 100 patients were around $US5 100 000 with an overall utility value of about 1700 quality-adjusted life years (QALYs). Both the lifetime costs and the utility values for the placebo (no treatment) group were very similar to those calculated for the mesalazine group.

Our cost-utility analysis showed that mesalazine maintenance therapy was associated with a cost of about $US5000 per QALY gained. There was, therefore, a small incremental benefit obtained, albeit with a very small incremental cost. Sensitivity analyses confirmed these results.

In conclusion, our study showed that long term maintenance therapy with mesalazine in patients with inactive Crohn’s disease should not be discouraged on the basis of preliminary cost-utility considerations. However, long term placebo-controlled studies of mesalazine are urgently needed to better define the long term prognosis of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994; 89: 692–8

    PubMed  CAS  Google Scholar 

  2. Caprilli R, Andreoli A, Capurso L, et al. 5-ASA in the prevention of Crohn’s disease postoperative recurrence: an interim report of the Italian Study Group of the Colon (GISC) [abstract]. Gastroenterology 1992; 102: A601

    Google Scholar 

  3. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435–9

    PubMed  CAS  Google Scholar 

  4. IMSG (International Mesalazine Study Group). Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn’s disease. Aliment Pharmacol Ther 1990; 4: 428–37

    Google Scholar 

  5. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease. Gastroenterology 1992; 103: 363–8

    PubMed  CAS  Google Scholar 

  6. Hay J, Hay A. Inflammatory bowel disease: cost of illness. J Clin Gastroenterol 1992; 14: 309–17

    Article  PubMed  CAS  Google Scholar 

  7. Hay J, Hay A. Inflammatory bowel disease: medical cost algorithms. Clin Gastroenterol 1992; 14: 318–27

    Article  CAS  Google Scholar 

  8. Pera A, Rocca B. Le malattie infiammatorie croniche intestinali: profili di diagnosi e terapia. Milano: EDRA srl, 1995

    Google Scholar 

  9. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn’s disease based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146–50

    Article  PubMed  CAS  Google Scholar 

  10. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn’s disease. Gastroenterology 1995; 108: 345–9

    Article  PubMed  CAS  Google Scholar 

  11. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine for the prevention of postoperative recurrence of Crohn’s disease. Aliment Pharmacol Ther 1994; 8: 35–43

    Article  PubMed  CAS  Google Scholar 

  12. Cooke WT, Mallas E, Prior P, et al. Crohn’s disease: course, treatment and longterm prognosis. Q J Med 1980; 195: 365–84

    Google Scholar 

  13. Depew WT, Medeiros J, Beck IT, et al. Clinical presentation and course of Crohn’s disease in southeastern Ontario. Can J Gastroenterol 1988; 2: 107–16

    Google Scholar 

  14. Farmer RG, Whelan G, Fazio WW. Long term follow-up of patients with Crohn’s disease: relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818–25

    PubMed  CAS  Google Scholar 

  15. Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn’s disease recurrences after intestinal resection with Eudragit-L-coated 5-aminosalicylic acid: preliminary results of a 1-year double-blind placebo-controlled study [abstract]. Gastroenterology 1991; 100: A208

    Google Scholar 

  16. Florent C, Cortot A, Modigliani R, et al. Placebo-controlled trial of Claversal in the prevention of early endoscopic relapse after curative resection for Crohn’s disease [abstract]. Gastroenterology 1992; 102: A623

    Google Scholar 

  17. Harper PH, Fazio WW, Lavery IC, et al. The long term outcome in Crohn’s disease. Dis Colon Rectum 1987; 30: 174–9

    Article  PubMed  CAS  Google Scholar 

  18. Heimann TM, Greenstein AJ, Lewis B, et al. Prediction of early symptomatic recurrence after intestinal resections in Crohn’s disease. Ann Surg 1993; 28: 294–9

    Article  Google Scholar 

  19. Krause U, Ejerbald S, Bergman L. Crohn’s disease. A long term study of the clinical course in 186 patients. Scand J Gastroenterol 1985; 20: 516–24

    Article  PubMed  CAS  Google Scholar 

  20. Lindhagen T, Ekelund G, Leandoer L, et al. Pre- and post-operative complications in Crohn’s disease with special references to duration of pre-operative disease history. Scand J Gastroenterol 1984; 19: 194–203

    PubMed  CAS  Google Scholar 

  21. Lochs H, Prainer CH, Westphal G, et al. Course and clinical features of Crohn’s disease. Dtsch Med Wochenschr 1985; 110: 1031–34

    Article  PubMed  CAS  Google Scholar 

  22. McLeod RS, Wolff BG, Steinhart H, et al. Delayed recurrence following surgery for Crohn’s disease [abstract]. Gastroenterology 1994; 106: A733

    Google Scholar 

  23. Okada M, Yao T, Fichigami T, et al. Anatomical involvement and clinical features in 91 Japanese patients with Crohn’s disease. J Clin Gastroenterol 1987; 9: 165–71

    Article  PubMed  CAS  Google Scholar 

  24. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331–5

    Article  PubMed  CAS  Google Scholar 

  25. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 665–72

    Article  PubMed  CAS  Google Scholar 

  26. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956–63

    PubMed  CAS  Google Scholar 

  27. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–40

    Article  PubMed  CAS  Google Scholar 

  28. DiComite L, Chiassino G. Elementi di demografia. Bari: Cacucci Editore 1995: 56–61

    Google Scholar 

  29. Tapinos G. Elementi di demografia. Milano: EGEA Spa, 1994: 186

    Google Scholar 

  30. Robinson R. Cost-effectiveness analysis. BMJ 1993; 307: 793–5

    Article  PubMed  CAS  Google Scholar 

  31. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418–24

    Article  PubMed  CAS  Google Scholar 

  32. Mark DB. Economic analysis methods and end-points. In: Califf RM, Mark DB, Wagner GS, editors. Acute coronary care in the thrombolytic era. St Louis: Mosby, 1995: 167–82

    Google Scholar 

  33. Schulman K, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic HIV infection. Ann Intern Med 1991; 114: 798–802

    PubMed  CAS  Google Scholar 

  34. Messori A, Becagli P, Trippoli S, et al. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51: 111–6

    Article  PubMed  CAS  Google Scholar 

  35. Wong JB, Koff RS, Tinè F, et al. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B-e-antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664–75

    PubMed  CAS  Google Scholar 

  36. Etchanson J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995; 332: 719–24.

    Article  Google Scholar 

  37. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Azienda Ospedaliera Careggi, viale Morgagni 85, 50134, Florence, Italy

    Giacomo Trallori

  2. Drug Information Centre, Azienda Ospedaliera Careggi, Florence, Italy

    Andrea Messori

Authors
  1. Giacomo Trallori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Messori
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trallori, G., Messori, A. Drug Treatments for Maintaining Remission in Crohn’s Disease. PharmacoEconomics 11, 444–453 (1997). https://doi.org/10.2165/00019053-199711050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711050-00006

Keywords

Search

Navigation